

Armin Koch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7851619/publications.pdf>

Version: 2024-02-01

54
papers

1,783
citations

304368

22
h-index

288905

40
g-index

56
all docs

56
docs citations

56
times ranked

3011
citing authors

#	ARTICLE	IF	CITATIONS
1	Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial. <i>Transplantation Direct</i> , 2022, 8, e1316.	0.8	7
2	Microbiota-associated Risk Factors for <i>Clostridioides difficile</i> Acquisition in Hospitalized Patients: A Prospective, Multicentric Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2625-e2634.	2.9	6
3	Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study. <i>Pharmaceutical Statistics</i> , 2021, 20, 675-691.	0.7	4
4	The use of external controls: To what extent can it currently be recommended?. <i>Pharmaceutical Statistics</i> , 2021, 20, 1002-1016.	0.7	33
5	Short term results of dynamic splinting for hallux valgus – A prospective randomized study. <i>Foot and Ankle Surgery</i> , 2020, 26, 146-150.	0.8	15
6	Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients. <i>Trials</i> , 2020, 21, 643.	0.7	9
7	The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders. <i>Frontiers in Psychiatry</i> , 2020, 11, 575826.	1.3	21
8	COVID-19 hits a trial: Arguments against hastily deviating from the plan. <i>Contemporary Clinical Trials</i> , 2020, 98, 106155.	0.8	3
9	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E – The HepNet SofE pilot study. <i>Journal of Hepatology</i> , 2020, 73, 696-699.	1.8	39
10	Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 51.	1.1	16
11	Risk factors for death in kidney transplant patients: analysis from a large protocol biopsy registry. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1171-1181.	0.4	17
12	Consequences of chronic kidney disease in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2019, 20, 151.	1.4	33
13	Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specification of mixed models for longitudinal data in study protocols. <i>Pharmaceutical Statistics</i> , 2019, 18, 636-644.	0.7	9
14	Digoxin mortality: randomized vs. observational comparison in the DIG trial. <i>European Heart Journal</i> , 2019, 40, 3336-3341.	1.0	48
15	Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve outcomes in patients with advanced) <i>Journal of Heart Failure</i> , 2019, 21, 676-684.	2.9	51
16	Ultrafine particles and ozone perturb norepinephrine clearance rather than centrally generated sympathetic activity in humans. <i>Scientific Reports</i> , 2019, 9, 3641.	1.6	15
17	Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSP/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and Parke. <i>Pharmaceutical Statistics</i> , 2019, 18, 140-144.	0.7	5
18	Commentary: On the levels of patient selection in registry-based randomized controlled trials. <i>Trials</i> , 2019, 20, 100.	0.7	10

#	ARTICLE	IF	CITATIONS
19	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 275-286.	4.6	128
20	Methods for evidence synthesis in the case of very few studies. <i>Research Synthesis Methods</i> , 2018, 9, 382-392.	4.2	132
21	Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 206.	1.2	37
22	Applicability and added value of novel methods to improve drug development in rare diseases. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 200.	1.2	12
23	How to use prior knowledge and still give new data a chance?. <i>Pharmaceutical Statistics</i> , 2018, 17, 329-341.	0.7	20
24	Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. <i>European Heart Journal</i> , 2017, 38, ehw577.	1.0	40
25	Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. <i>Respiratory Research</i> , 2017, 18, 60.	1.4	15
26	A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 102.	1.2	5
27	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 215-222.	4.6	109
28	Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences Comorbidities Network Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 189-197.	2.5	81
29	Non-invasive fibrosis score for hepatitis delta. <i>Liver International</i> , 2017, 37, 196-204.	1.9	42
30	Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. <i>Respiratory Research</i> , 2017, 18, 171.	1.4	27
31	Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 140.	1.2	10
32	The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort. <i>International Journal of COPD</i> , 2017, Volume 12, 3437-3448.	0.9	19
33	Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies. <i>Respiratory Research</i> , 2016, 17, 81.	1.4	25
34	ACEMg-mediated hearing preservation in cochlear implant patients receiving different electrode lengths (PROHEARING): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 394.	0.7	4
35	A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 312.	0.7	28
36	The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. <i>Respiratory Medicine</i> , 2016, 114, 27-37.	1.3	113

#	ARTICLE	IF	CITATIONS
37	Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. <i>BMC Pulmonary Medicine</i> , 2016, 16, 70.	0.8	81
38	Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. <i>Blood</i> , 2016, 127, 2289-2297.	0.6	48
39	Perioperative Bromelain Therapy after Wisdom Teeth Extraction – A Randomized, Placebo-Controlled, Double-Blinded, Three-Armed, Cross-Over Dose-Finding Study. <i>Phytotherapy Research</i> , 2016, 30, 2012-2019.	2.8	21
40	Does it help that efficacy has been proven once we start discussing (added) benefit?. <i>Biometrical Journal</i> , 2016, 58, 89-103.	0.6	0
41	Partial verification bias and incorporation bias affected accuracy estimates of diagnostic studies for biomarkers that were part of an existing composite gold standard. <i>Journal of Clinical Epidemiology</i> , 2016, 78, 73-82.	2.4	17
42	Fallback tests for co-primary endpoints. <i>Statistics in Medicine</i> , 2016, 35, 2669-2686.	0.8	13
43	The Benefit of Baseline Staging-Risk Assessment of Distant Breast Cancer Metastases by Tumor Stage. <i>Anticancer Research</i> , 2016, 36, 4909-4914.	0.5	1
44	No solution yet for combining two independent studies in the presence of heterogeneity. <i>Statistics in Medicine</i> , 2015, 34, 2476-2480.	0.8	57
45	Respiratory tract exacerbations revisited: Ventilation, inflammation, perfusion, and structure (VIPS) monitoring to redefine treatment. <i>Pediatric Pulmonology</i> , 2015, 50, S57-65.	1.0	29
46	Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. <i>Blood</i> , 2015, 125, 1091-1097.	0.6	197
47	Non-invasive diagnosis of acute rejection in renal transplant patients using mass spectrometry of urine samples - a multicentre phase 3 diagnostic accuracy study. <i>BMC Nephrology</i> , 2015, 16, 153.	0.8	10
48	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEx Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0128069.	1.1	5
49	Reliably Basing Conclusions on Subgroups of Randomized Clinical Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 42-57.	0.4	21
50	Effects of ultrafine particles on the allergic inflammation in the lung of asthmatics: results of a double-blinded randomized cross-over clinical pilot study. <i>Particle and Fibre Toxicology</i> , 2014, 11, 39.	2.8	26
51	Unblinded Adaptive Statistical Information Design Based on Clinical Endpoint or Biomarker. <i>Statistics in Biopharmaceutical Research</i> , 2013, 5, 293-310.	0.6	19
52	No inconsistent trial assessments by NICE and IQWiG: different assessment goals may lead to different assessment results regarding subgroup analyses. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 1305-1307.	2.4	18
53	Confirmatory Clinical Trials with an Adaptive Design. <i>Biometrical Journal</i> , 2006, 48, 574-585.	0.6	25
54	Why Are Some Meta-Analyses More Credible Than Others?. <i>Drug Information Journal</i> , 2001, 35, 1019-1030.	0.5	4